SGHT vs. AXGN, SIBN, BVS, AVNS, ZIMV, KIDS, TMCI, CBLL, SMLR, and DCTH
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), CeriBell (CBLL), Semler Scientific (SMLR), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.
Sight Sciences vs. Its Competitors
Sight Sciences (NASDAQ:SGHT) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.
AxoGen has a net margin of -2.29% compared to Sight Sciences' net margin of -64.23%. AxoGen's return on equity of -4.43% beat Sight Sciences' return on equity.
Sight Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 2.8% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Sight Sciences and Sight Sciences both had 9 articles in the media. AxoGen's average media sentiment score of 1.26 beat Sight Sciences' score of 0.50 indicating that AxoGen is being referred to more favorably in the news media.
AxoGen has higher revenue and earnings than Sight Sciences. AxoGen is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
Sight Sciences currently has a consensus target price of $4.42, suggesting a potential upside of 27.65%. AxoGen has a consensus target price of $26.00, suggesting a potential upside of 58.44%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Sight Sciences.
Summary
AxoGen beats Sight Sciences on 11 of the 14 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 9/12/2025 by MarketBeat.com Staff
